Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Aug 6, 2009

Premium

Title: siRNA Targeting Gremlin

Number: 7,569,684

Filed: March 30, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CKSF1B1."


Title: Compositions and Methods for siRNA Inhibition of HIF-1 Alpha

Number: 20090191263

Filed: Jan. 26, 2009

Lead Inventor: Samuel Reich, University of Pennsylvania (Opko Health)

The invention, the patent application's abstract states, relates to "RNA interference using small interfering RNAs [targeting] HIF-1 alpha mRNA, [which can] inhibit expression of the HIF-1 alpha gene.

"As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited," the abstract notes. "Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, particularly in diseases such as diabetic retinopathy, age-related macular degeneration, and many types of cancer."


Title: siRNA Targeting Connective Tissue Growth Factor

Number: 20090191625

Filed: Jan. 23, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF."


Title: miR-21-Regulated Genes and Pathways as Targets for Therapeutic Intervention

Number: 20090192102

Filed: May 14, 2008

Lead Inventor: Andreas Bader, Asuragen

The invention "concerns methods and compositions for identifying genes or genetic pathways modulated by miR-21, using miR-21 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient, and/or treating the patient with an appropriate miRNA," the patent application's abstract states.


Title: Multi-Targeting Interfering RNAs Having Two Active Strands and Methods for Their Design and Use

Number: 20090192103

Filed: May 21, 2008

Lead Inventor:
Laurent Pierre Rivory, Johnson & Johnson Research

"Interfering RNA molecules are now designed and produced with specificity for multiple binding sequences present in distinct genetic contexts in one or more pre-selected target RNA molecules and are used to modulate expression of the target sequences," the patent application's abstract states. "The multi-targeting interfering RNA molecules have two strands that target multiple target sites on one or more pre-selected RNA molecules. Such a multi-targeting interfering RNA approach provides a powerful tool for gene regulation."


Title: RNA Interference-Mediated Inhibition of Hypoxia-Inducible Factor 1 Gene Expression Using Short Interfering Nucleic Acid

Number: 20090192104

Filed: July 17, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating hypoxia-inducible factor gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of HIF1 gene expression and/or activity by RNA interference using small nucleic acid molecules."


Title: RNA Interference-Mediated Inhibition of Intracellular Adhesion Molecule Gene Expression Using Short Interfering Nucleic Acid

Number: 20090192105

Filed: July 17, 2008

Lead Inventor:
James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating intercellular adhesion molecule gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ICAM gene expression and/or activity by RNA interference using small nucleic acid molecules."


Title: Modulation of eIF4E Expression

Number: 20090192106

Filed: Aug. 1, 2008

Lead Inventor: Kenneth Dobie, Eli Lilly

The patent application, its abstract states, claims "oligomeric compounds, compositions and methods … for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded, and are targeted to nucleic acid encoding eIF4E." Also claimed are "methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E," according to the abstract.


Title: miR-124-Regulated Genes and Pathways as Targets for Therapeutic Intervention

Number: 20090192111

Filed: Dec. 1, 2008

Lead Inventor: Andreas Bader, Asuragen

The invention, the patent application's abstract states, "concerns methods and compositions for identifying genes or genetic pathways modulated by miR-124, using miR-124 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient, and/or treating the patient with an appropriate miRNA."


Title: Compositions and Methods for Treating Cancer

Number: 20090192112

Filed: Dec. 12, 2008

Lead Inventor: Diane Simeone, University of Michigan

The invention "relates to therapeutic targets for cancer … in particular, to small molecules and nucleic acids that target ATDC expression in cancer with ATDC over-expression," according to the patent application's abstract.

The application specific claims an RNAi oligo that alters ATDC activity.


Title: Interfering RNA Duplexes Having Blunt Ends and 3' Modifications

Number: 20090192113

Filed: Dec. 18, 2008

Lead Inventor: Jan Weiler, Novartis

The invention, the patent application's abstract states, relates to "double-stranded RNA compounds with at least one blunt end comprising at least one 3' end [of a specific design] … and wherein said double-stranded RNA mediates RNA interference."


Title: miR-10-Regulated Genes and Pathways as Targets for Therapeutic Intervention

Number: 20090192114

Filed: Dec. 19, 2008

Lead Inventor: Dmitriy Ovcharenko, Asuragen

The invention "concerns methods and compositions for identifying genes or genetic pathways modulated by miR-10, using miR-10 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient, and/or treating the patient with an appropriate miRNA," the patent application's abstract states.


Title: Use of Compounds That Interfere with the Hedgehog Signaling Pathway for the Manufacture of a Medicament for Preventing, Inhibiting, and/or Reversing Ocular Diseases Related with Ocular Neovascularization

Number: 20090192115

Filed: Jan. 2, 2009

Lead Inventor: Alberto Auricchio, Fondazione Telethon

The invention comprises "compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization," the patent application's abstract states. "Particularly, the above-mentioned diseases are wet age-related macular degeneration, proliferative diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity."


Title: Tak1-D-Mediated Induction of Cell Death in Human Cancer Cells by Specific Sequence Short Double-Stranded RNAs

Number: 20090192118

Filed: Jan. 28, 2009

Lead Inventor: Reinhard Kodym, University of Texas Southwestern Medical Center

"The splicing variant D of the TAK1 gene is activated by short double-stranded RNAs in a sequence-specific manner," according to the patent application's abstract. "Activation of Tak1-D leads to the downstream activation of the p38 MAPK and of SAPK/JNK, but not the NF-kappa-B pathway. The current invention therefore provides a method of inducing apoptosis and/or cell cycle arrest in a cancer cell comprising contacting said cell with an agonist of Tak1-D function.

"The invention further provides a method of modulating inflammation and the treatment of cancer by the administration of an agonist of Tak1-D function or expression," the abstract adds. "In yet another aspect, the invention provides a method of inducing p38 MAPK and SAPK/JNK signaling in a cell comprising contacting said cell with an agonist of Tak1-D function or expression."


Title: Methods and Compositions for RNA Interference

Number: 20090193531

Filed: May 16, 2008

Lead Inventor: David Beach, Cold Spring Harbor Laboratory

The invention provides "methods for attenuating gene expression in a cell using gene-targeted double stranded RNA," the patent application's abstract states. "The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited."

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.